Epizyme Reports Business Progress and Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Epizyme (EPZM) Tops Q3 EPS by 5c, Revenues Miss
November 6, 2020 6:43 AM ESTEpizyme (NASDAQ: EPZM) reported Q3 EPS of ($0.55), $0.05 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $3.57 million versus the consensus estimate of $5.43 million.
2020 has been a year of big milestones for Epizyme, and we are executing our TAZVERIK® launches well,... More
